Metastasis of tumor to adjacent organs is the major cause of death and almost 20% of the patients diagnosed with CRC have metastasis.1,2 The current options for targeted therapies are very limited such as anti-Vascular Endothelial Growth Factor (VEGF), Anti-Epidermal Growth Factor Receptor (EGFR) and anti-Programmed Cell Death-1 (PD1) but only a fraction of patients respond to the therapies. The gene discussed is VEGFA; the disease is neoplasm.